NCT02462109View on ClinicalTrials.gov

Catatonia in Nodding Syndrome and Lorazepam Treatment

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
CatatoniaNodding Syndrome
Interventions
DRUG

Lorazepam

Lorazepam was given based on the weight of the child with Catatonia. The lower dose (0.5 mg) was used as starting dose for patients with \<30 kg body weight, while the higher dose (1 mg) as the starting dose for patients with \>30 kg body weight.

All Listed Sponsors
collaborator

University of Mississippi Medical Center

OTHER

lead

Makerere University

OTHER

NCT02462109 - Catatonia in Nodding Syndrome and Lorazepam Treatment | Biotech Hunter | Biotech Hunter